JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
+0.31 (+0.23%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close137.52
Bid0.00 x 800
Ask0.00 x 1300
Day's Range136.46 - 138.49
52 Week Range118.62 - 148.99
Avg. Volume6,781,038
Market Cap367.01B
Beta (3Y Monthly)0.69
PE Ratio (TTM)25.54
EPS (TTM)5.40
Earnings DateJul 16, 2019
Forward Dividend & Yield3.60 (2.58%)
Ex-Dividend Date2019-02-25
1y Target Est145.44
Trade prices are not sourced from all markets
  • Checking in on trade war's impact on the markets
    Yahoo Finance Video5 days ago

    Checking in on trade war's impact on the markets

    GuideStone Capital Management President David Spika joins Yahoo Finance's Adam Shapiro, Julie Hyman, Jared Blikre, and MIT Professor Sinan Aral.

  • Beauty: A Key Growth Driver of JNJ’s Consumer Segment in Q1
    Market Realist9 hours ago

    Beauty: A Key Growth Driver of JNJ’s Consumer Segment in Q1

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performance In the first quarter, Johnson & Johnson’s (JNJ) Consumer segment reported 2.2% YoY (year-over-year) growth in worldwide

  • What Are Analysts Recommending for Johnson & Johnson?
    Market Realist11 hours ago

    What Are Analysts Recommending for Johnson & Johnson?

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Stock price movementsOn April 17, Johnson & Johnson (JNJ) closed at $138.52, 0.36% higher than its previous closing price, 16.78% higher than its

  • JNJ or PFE: Comparing Legacy and Newly Launched Immunology Drugs
    Market Realist11 hours ago

    JNJ or PFE: Comparing Legacy and Newly Launched Immunology Drugs

    Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Legacy immunology drugs In the first quarter, Johnson & Johnson (JNJ) reported Remicade sales worth $1.10 billion, a YoY (year-over-year) fall of 20.6% on

  • JNJ Surpassed Consensus Estimates in the First Quarter
    Market Realist13 hours ago

    JNJ Surpassed Consensus Estimates in the First Quarter

    Is Johnson & Johnson an Attractive Buy following Its Q1 Results?Revenue performance Johnson & Johnson (JNJ) reported its earnings results for the first quarter of 2019 on April 16. In its first-quarter earnings press release, the company

  • Miguel Patricio: 10 Things to Know About the New Kraft Heinz CEO
    InvestorPlace13 hours ago

    Miguel Patricio: 10 Things to Know About the New Kraft Heinz CEO

    There's a new Kraft Heinz CEO that will be leading the company in the near future.Here's what we know about the new CEO for Kraft Heinz (NASDAQ:KHC). * The new Kraft Heinz CEO is Miguel Patricio. * He will be taking over as the CEO of the company starting on July 1, 2019. * This will have him taking over the position from Bernardo Hees, who will remain with the company as its CEO until June, 30, 2019. * Patricio is joining the company as the new Kraft Heinz CEO after spending two decades with Anheuser-Busch InBev (NYSE:BUD). * During his time with Anheuser-Busch InBev, Patricio served in various roles as part of its Executive Leadership team. * These roles include him serving as the company's Global Chief Marketing Officer from 2012 to 2018. * Prior to his, he was serving as the President of Asia Pacific from 2008 to 2012 for Anheuser-Busch InBev. * Before serving in that role, he was the President of North America for Anheuser-Busch InBev from 2006 to 2008. * Before starting his career at Anheuser-Busch InBev, Patricio worked at several other consumer companies. * Among these companies are Philip Morris (NYSE:PM), Coca-Cola (NYSE:KO) and Johnson & Johnson (NYSE:JNJ). * 7 Tech Stocks With Too Much Risk, Not Enough Upside You can follow this link to learn more about new Kraft Heinz CEO Miguel Patricio and the experience he is bringing to the company.InvestorPlace - Stock Market News, Stock Advice & Trading TipsKHC stock started the day off up 1% on Monday morning, but is now largely unmoved as of the afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Miguel Patricio: 10 Things to Know About the New Kraft Heinz CEO appeared first on InvestorPlace.

  • Benzinga15 hours ago

    6 Cannabis Execs On The Strengths Of Their Businesses

    Vertical Companies is among the largest vertically integrated businesses within the legal medical cannabis industry. The company is focused on "doing all things with the plant" except for operating a retail presence, said CEO Smoke Wallin.

  • JNJ or PFE: Comparing Their Fastest-Growing Immunology Drugs
    Market Realist15 hours ago

    JNJ or PFE: Comparing Their Fastest-Growing Immunology Drugs

    Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Immunology revenue performance In the first quarter, Johnson & Johnson (JNJ) reported immunology sales of $3.25 billion, a YoY (year-over-year) rise of

  • JNJ or PFE: Which Has Better EPS Guidance for 2019?
    Market Realist17 hours ago

    JNJ or PFE: Which Has Better EPS Guidance for 2019?

    Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)EPS guidance In its first-quarter earnings press release, Johnson & Johnson (JNJ) raised the guidance for its adjusted diluted operational EPS from its

  • Johnson & Johnson posts strong revenue in 1Q
    Associated Press2 days ago

    Johnson & Johnson posts strong revenue in 1Q

    Lower sales overseas and higher costs for research and litigation pushed Johnson & Johnson's first-quarter profit down 14%, but the health care giant beat profit and revenue expectations, pushing up its ...

  • Asian shares edge lower despite encouraging China GDP data
    Associated Press2 days ago

    Asian shares edge lower despite encouraging China GDP data

    Major share benchmarks were mostly lower in Asia on Wednesday after China announced its economy grew at a 6.4% annual pace in the last quarter. Japan's Nikkei 225 index gained 0.3% to 22,289.32 and the ...

  • Financial Times2 days ago

    Revamp at Silence does little to improve investors’ wellbeing

    Silence is more “of the lambs” than golden at Aim-quoted Silence Therapeutics. Shares in the biotechnology company, which is backed by an array of high-profile institutional investors including Woodford and Invesco, have fallen from close to 250p to 58p in 18 months. Last August, Annalisa Jenkins quit after being chairwoman for 10 months.

  • 5 Top Pharmaceutical Stocks to Buy in 2019
    Motley Fool3 days ago

    5 Top Pharmaceutical Stocks to Buy in 2019

    Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.

  • The Top 10 Biotechnology Companies (JNJ, ROG.VX)
    Investopedia4 days ago

    The Top 10 Biotechnology Companies (JNJ, ROG.VX)

    Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

  • TheStreet.com4 days ago

    Be Careful With Healthcare Stocks Here

    CEO David Wichmann on his company's earnings conference call Tuesday: "Medicare For All." UNH shares had been bid up in Tuesday morning trade on the back of earnings and revenues that exceeded analyst estimates. Want to be alerted before Jim Cramer buys or sells JNJ or UNH?

  • Benzinga5 days ago

    Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion

    Zoom Technologies Inc (OTC: ZOOM ) traded higher by as much as 120 percent Thursday morning after popular video and audio platform Zoom Video Communications Inc (NASDAQ: ZM ) held its highly anticipated ...

  • Here Are the Key Takeaways From J&J's Q1 Earnings Report
    Zacks5 days ago

    Here Are the Key Takeaways From J&J's Q1 Earnings Report

    Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.

  • Reuters5 days ago

    Idorsia confirms 2019 spending plan as clinical trials "on track"

    Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects. Idorsia founder Chief Executive Jean-Paul Clozel has Phase III studies of drugs for insomnia, rare Fabrys disease, hypertension and brain bleeding.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of JNJ earnings conference call or presentation 16-Apr-19 12:30pm GMT

    Q1 2019 Johnson & Johnson Earnings Call

  • Liability Issues Weigh on Johnson & Johnson
    Investopedia6 days ago

    Liability Issues Weigh on Johnson & Johnson

    Johnson & Johnson relinquished the majority of gains after a post-earnings rally, held down by baby powder liability fears.

  • Benzinga6 days ago

    Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

    Johnson & Johnson (NYSE: JNJ ) kickstarted the large-cap pharma earnings season Tuesday with forecast-beating first-quarter results. The company narrowed its full-year earnings per share guidance but maintained ...

  • Stock Market News For Apr 17, 2019
    Zacks6 days ago

    Stock Market News For Apr 17, 2019

    Markets closed higher on Tuesday as investors welcomed a spate of healthy first quarter earnings results.

  • Investing.com6 days ago

    StockBeat - UnitedHealth Deepens Losses as Fears Over Political Risk Rise - UnitedHealth Group fell deeper into the red Wednesday as analysts turned bearish on the stock in the wake of its CEO's warning on political risk.

  • 10 Best Stocks to Buy and Hold Forever
    InvestorPlace6 days ago

    10 Best Stocks to Buy and Hold Forever

    [Editor's note: This story was previously published in March 2019. It has since been updated and republished.]In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place.And yet, for better or worse, that's the mindset all of us should adopt for most of our investing capital. More often than not, the more you trade, the worse you end up doing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt has been said (and verified) that 95% of true "day traders" -- the most aggressive and active of all market participants -- end up losing money by being too active for their own good. Conversely, the fact that Warren Buffett's favorite holding period is "forever" and how he's got a track record most investors would envy is just as telling. * 10 S&P 500 Stocks to Weather the Earnings Storm With that as the backdrop, here's a rundown of 10 stocks to buy and hold forever … or at least until something significant changes with your life plans or the companies themselves.Source: Shutterstock AT&T (T)Dividend Yield: 6.33% Year-to-date gain: 9.3%Calling a spade a spade, shares of telecom giant AT&T Inc. (NYSE:T) haven't been easy to own in a while. The stock is down 14% from its mid-2016 peak, while most other stocks are well up for the timeframe. The impasse has been an increasingly tougher wireless and broadband market. But now that plans to acquire media outfit Time Warner Inc (NYSE:TWX) look good a turnaround might have begun.If your intended timeframe really is "forever" though, a tough couple of years is nothing … particularly considering you're collecting a healthy dividend yield on your position's current value.More than that though, this is a telco name with a lot of clout, and a little more than $50 billion in the bank. And, if/when the Time Warner deal goes through, it will have yet another revenue-bearing weapon in its arsenal.Source: Shutterstock Alphabet (GOOGL, GOOG)Dividend Yield: N/A Year-to-date gain: 17.25%Fans and followers of the company will likely know that Google parent company Alphabet Inc (NASDAQ:GOOGL, NASDAQ:GOOG) beat last quarter's earnings estimate, posting $12.77 per share. What got lost in the shuffle is how operating margains fell to 21 % from last quarter's 24%. * 7 Stocks to Buy for Spring Season Growth Appreciated or not, Alphabet is a profit and revenue growth machine that has earned its spot on a list of "forever" stocks to buy. It may not always beat estimates, but it does always increase its numbers. That's because it keeps finding a way to serve as the middleman for about 70% of web searches done on desktops, and boasts being the preferred search engine for about 90% of the queries made via a mobile device.If it was going to be toppled, we'd see evidence of it by now.Source: Shutterstock 3M (MMM)Dividend Yield: 2.64% Year-to-date gain: 14.13%In an era where complicated companies are shedding disparate parts of themselves so each arm can be hyper-focused on doing one thing exceedingly well, 3M Co (NYSE:MMM) is something of an outlier. It offers everything from office supplies to healthcare products to the power transformers you see perched on top of power-line poles.It's wild mix that seems to work for 3M though, giving the company something to sell regardless of the economic environment.The clincher: 3M has managed to pay and increase its dividend every year going all the way back to 1977.Source: Shutterstock Walmart (WMT)Dividend Yield: 2.06% Year-to-date gain: 9.9%Yes, the advent of, Inc. (NASDAQ:AMZN) has proven problematic for the world's biggest retailer, Walmart Inc (NYSE:WMT). Rumors of Walmart's death at the hands of Amazon, however, have been greatly exaggerated.After being knocked over a few years ago, the company has regrouped, having figured out a way to fight the ever-growing reach of its online rival. The evidence? Last quarter's same-store sales grew 2.6%. Per-share profits missed estimates, to be clear, but much of that miss can be attributed to investments the retailer has been making in itself. * 7 Marijuana Companies: Which Pot Stocks Should You Buy? While it has been an ugly battle at times, Walmart has finally learned how to compete with The fact that it can leverage its stores to do so only bolsters the bullish case. Southern Co (SO)Source: Shutterstock Dividend Yield: 4.74% Year-to-date gain: 19.6%No list of stocks to buy and hold forever would be complete without a utility stock. In good times and bad, consumers almost always pay their electricity bill. And, even though margins are thin and power providers don't have a ton of pricing power, they have little competition in most markets. Most requests for rate hikes are also approved without question.To that end, Southern Co (NYSE:SO) is one of the top picks of the litter.Southern serves nine million customers, mostly in the south, although it's represented in most of the major regions of the United States. More important, Southern Co has dished out stunningly consistent (even if tiny) profit growth, setting the stage for equally consistent dividends. It has not failed to increase its annual payout since the late 90's.Source: Shutterstock Johnson & Johnson (JNJ)Dividend Yield: 2.60% Year-to-date gain: 8.46%As advanced as we've become as a society, the need for medicines, surgical products and simple healthcare solutions like Band-Aids and Tylenol is never going to go away. That means Johnson & Johnson (NYSE:JNJ) -- which maintains a bigger product portfolio than most investors realize -- will always have something to sell to someone.That being said, don't think for a minute that a play on J&J is capitulation in the search for respectable growth. The company isn't just about treating tummy troubles and selling no-tears baby shampoo. * 7 AI Stocks to Watch with Strong Long-Term Narratives It still operates a pharmaceutical arm as well, with rheumatoid arthritis and Crohn's disease drug Remicade and blood-thinner Xarelto both driving more than $1 billion in annual sales for the company.Source: Shutterstock Berkshire Hathaway (BRK.B, BRK.A)Dividend Yield: N/A Year-to-date gain: 4.43%If the Warren Buffett mindset is the underlying philosophy in play here, why not go straight to the source and buy a piece of the fund he built from the ground up? That's Berkshire Hathaway Inc. (NYSE:BRK.B, NYSE:BRK.A).Sure, in his most recent letter to shareholders, the Oracle of Omaha said he's struggling to find new companies at a "sensible purchase price," which is the life-blood of the organization's growth. There's also the stark reality that the 87-year-old Buffett is increasingly less involved with Berkshire Hathaway. That separation is only going to widen as time marches on.Still, he has more than proven his way works for the long haul. Over the course of the past half-century, Berkshire stock has performed about twice as well as the S&P 500 has.Source: Shutterstock Waste Management (WM)Dividend Yield: 1.96% Year-to-date gain: 18%There's an old adage … the only two sure things in life are death and taxes.It's a humorous point about the limited nature of human life and the far-reaching power of the IRS. But, it's not necessarily a complete cliche. There's a third certainty. That is, as long as people are living on the planet earth, they'll be creating garbage to shuttle to their nearby landfill.Enter Waste Management, Inc. (NYSE:WM), which runs garbage-pickup services for 21 million North American customers. Although its top and bottom lines ebb and flow, the bigger trend for both is pointed upward. * 10 Dow Jones Stocks Holding the Blue Chip Index Back Look for more of the same too. As CEO Jim Fish pointed out late last month, "The babyboomers are coming into a period of heavy medical spend. All of our parents are aging and spending more on medical spend. There is medical waste generated from that, we are in that business. The industrial economy is important to us.Whether it's through repatriation from the new tax law, or just through the fact the U.S. and Canada are great places to do business and the industrial economy is showing some signs of life, we are a big industrial player on the back-end of the cycle."Source: Shutterstock American Water Works (AWK)Dividend Yield: 1.78% Year-to-date gain: 15.03%Perhaps just as certain as death, taxes and the creation of trash, as long as people are alive they're going to need water to survive. That puts a water utility name like American Water Works Company Inc (NYSE:AWK) in the catbird seat.Much like electricity providers Southern Company, American Water Works Company -- which offers water and sewer services to 15 million people in the United States -- is rarely told no when it wants to raise rates. Water service prices have risen at above-inflation rates for the past several years, and American Water Works Company has benefitted from that industry-wide trend. It's not apt to change anytime soon.Source: Shutterstock Colgate-Palmolive (CL)Dividend Yield: 2.50% Year-to-date gain: 16%Last but not least, while the purchase of things like cars are cyclical, and the automobile industry itself is subject to constant reinvention, there are some consumer goods people just buy over and over again without a second thought. Among those often-repurchased items are Colgate toothpaste, Palmolive dish soap, Speed Stick deodorant and Cuddly fabric conditioner.Yep, they're all made by Colgate-Palmolive Company (NYSE:CL), though they're only a small sampling of the brands you'll find under the company's umbrella. * 7 High-Risk Stocks With Big Potential Rewards Those who know the Colgate-Palmolive story well will know the company has gotten into some sloppy spending habits, crimping margins more than most shareholders would like. That's starting to change, however, with a serious and rather impressive cost-cutting initiative. The benefits of that work could last years, if not decades.As of this writing, James Brumley hold a long position in AT&T. You can follow him on Twitter, at @jbrumley.Compare Brokers The post 10 Best Stocks to Buy and Hold Forever appeared first on InvestorPlace.

  • Is More Downside Ahead for Boeing Stock? Should You Buy?
    InvestorPlace6 days ago

    Is More Downside Ahead for Boeing Stock? Should You Buy?

    The news surrounding Boeing (NYSE:BA) is no secret at this point. The 737 MAX has some serious issues that have resulted in massive backlash against the jet maker. To be honest, Boeing stock hasn't suffered as big of a blow as some would have thought, as support continues to lift BA.Source: Shutterstock Does that mean it's time to buy? Let's look at what's happening. Boeing's 737 MAX IssueLast fall, a 737 MAX operated by Lion Air crashed, killing all on board. There were concerns by pilots, but it didn't stop airlines from keeping the 737 MAX operating in their fleet. Another accident involving the 737 Max occurred in March, with Ethiopian Air suffering a crash, leaving no survivors.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Marijuana Companies: Which Pot Stocks Should You Buy? This caused the industry to awake from its slumber, with countries and airlines quickly grounding their 737 MAX fleet. This is a terrible optic for the aircraft manufacturer, and it's about to hit Boeing's bank account.For a moment, forget about the possible order cancellations, potentially lower prices and lawsuits Boeing will face. According to their first-quarter deliveries report, the company did not log one new order for the 737 MAX in March. This isn't some hokey jet at the bottom of its catalog, either. The MAX is Boeing's fastest-selling unit right now. For the order line to dry up instantly says everything about what the industry thinks about the embattled airplane.If the solution isn't a simple software fix, Boeing's sales and earnings could be at stake. Not that it will bankrupt the company, but it will cause some investors to rethink Boeing stock in the near term.More likely than not, BA will get through the 737 MAX issue in the same way that Johnson & Johnson (NYSE:JNJ), McDonald's (NYSE:MCD) or Disney (NYSE:DIS) and other blue-chip names get through issues like this. But that doesn't mean it may not suffer more before moving past it. Trading BA Stock Price Click to Enlarge The 737 MAX has become a short-term focus, but it could become a longer-term worry. That's why we're looking at two charts, the six-month daily (above) and a 30-month weekly chart (below). I have updated these charts from my prior outlook earlier this month.As you can see on the short-term chart, Boeing stock continues to bounce with each test of that $362-ish level. It's just above the 200-day moving average at $359, but BA stock is struggling to move higher. It put in a lower high earlier this month when it failed to reclaim the 50 DMA. If momentum fades here, it will secure another lower high and increase the odds that shares will break below support.Then what?That's where the longer-term chart comes into play. There's support in the low $360s, while the 50-week moving average is at $357. Click to Enlarge This 50-week/200-day combo should be enough to buoy Boeing stock on its first test. However, if there's a gap down below this level, BA stock may quickly find itself back in its prior range.This rangebound action persisted for most of 2018, keeping the Boeing stock price between $315 and $360. The occasional break below range support was met with buyers, and you can see how BA shares have been finding prior-range resistance as current support.If support does hold up, we need to see the Boeing stock price push through the 10-week moving average and get above its 50 DMA. Until then, a break below prior resistance/current support is a possibility. Bottom Line on BA StockBoeing stock will report earnings on April 24. It's hard to imagine investors finding a sudden wave of confidence ahead of that report. The only exception? Perhaps management giving the all-clear and global airlines announcing the re-addition of the 737 MAX to their fleet.Estimates currently call for revenue to grow 2.4% to $23.95 billion in the quarter, driving earnings of $3.59 per share. This EPS estimate calls for a 1.4% decline year-over-year, and has fallen from $4.30 per share over the last 30 days, a 16.5% decline.The full-year estimates have also come down, although not as much. Full-year expectations now call for earnings of $17.81 per share. This is down almost 12% over the past 30 days from $20.21 per share. However, this would represent growth of more than 11% YOY, while revenue is still expected to grow 4.6% for 2019.BA is still a cash flow machine. It runs a very profitable outfit and has a deep backlog of new orders. Even with the disruption to the 737 MAX, this backlog should remain robust and keep Boeing's long-term trajectory intact. That said, full-year estimates are perhaps the biggest risk to BA stock. If management comes out with a disappointing outlook or admits business-related headwinds, watch out! Covering analysts will likely cut their full-year expectations.If that happens, Boeing stock could come under pressure and fall below those key support levels we highlighted. Of course, the opposite is possible too.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for Spring Season Growth * This Is How You Beat Back a Bear Market * 7 Dental Stocks to Buy That Will Make You Smile Compare Brokers The post Is More Downside Ahead for Boeing Stock? Should You Buy? appeared first on InvestorPlace.